PDGFR β inhibitor

DRUG CLASS:

PDGFR β inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3-ITD mutation + MLL fusion + TP53 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL fusion + TP53 mutation	Acute Myelogenous Leukemia	sorafenib + ARO-002 Sensitive: C3 – Early Trials sorafenib + ARO-002 Sensitive : C3	sorafenib + ARO-002 Sensitive: C3 – Early Trials sorafenib + ARO-002 Sensitive : C3
PDGFRB overexpression	Colorectal Cancer	PDGFRB overexpression	Colorectal Cancer	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA R841K	Melanoma	PDGFRA R841K	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA V658A	Melanoma	PDGFRA V658A	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA P577S	Melanoma	PDGFRA P577S	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA H845Y	Melanoma	PDGFRA H845Y	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
PDGFRA G853D	Melanoma	PDGFRA G853D	Melanoma	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ARO-002 + Wu-5 Sensitive: D – Preclinical ARO-002 + Wu-5 Sensitive : D	ARO-002 + Wu-5 Sensitive: D – Preclinical ARO-002 + Wu-5 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D
FLT3 Y842C	Acute Myelogenous Leukemia	FLT3 Y842C	Acute Myelogenous Leukemia	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D
FLT3 N676D	Acute Myelogenous Leukemia	FLT3 N676D	Acute Myelogenous Leukemia	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D
FLT3 N676D + FLT3 Y842C	Acute Myelogenous Leukemia	FLT3 N676D + FLT3 Y842C	Acute Myelogenous Leukemia	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D	sorafenib + ARO-002 Sensitive: D – Preclinical sorafenib + ARO-002 Sensitive : D
FLT3 N676T	Acute Myelogenous Leukemia	FLT3 N676T	Acute Myelogenous Leukemia	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D
FLT3 D698N	Acute Myelogenous Leukemia	FLT3 D698N	Acute Myelogenous Leukemia	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D	ARO-002 Sensitive: D – Preclinical ARO-002 Sensitive : D

PDGFR β inhibitor

PDGFR β inhibitor

Associations(25)

Associations
(25)